Last year, the rumor that Pascal Soriot had to change to the CEO of Teva was very rampant, and the reasons for his departure were constant. Pascal Soriot himself declined to comment directly on the matter and later sent an internal memo to the staff, urging them to continue… Continue Reading Rumors: AstraZeneca will replace the CEO? Successor candidates may be generated internally
On June 12, Lilly/AstraZeneca announced the termination of the global phase III project for the treatment of Alzheimer’s disease with lanabecestat (oral BACE inhibitor). Lilly and AstraZeneca reached an alliance to develop lanabecestat in 2014. Lilly is mainly responsible for clinical development work. AstraZeneca is mainly responsible for pharmaceutical production.… Continue Reading Another phase III drug for Alzheimer’s disease failed! BACE target failure rate exceeds 80%
Viagra From the failure of cardiovascular medications to the great success of ED indications In the 1980s, scientists at Pfizer’s European Research Center have been looking for drugs to treat cardiovascular diseases such as angina. The commonly used nitrates at that time were prone to tolerance. At that time, basic… Continue Reading How did innovative drugs fail from Viagra to PD-1?